BECOTATUG VEDOTIN
UNII VHA6L8H5FM

Substance Identification & Data

This profile provides standardized clinical and technical data for Becotatug Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) VHA6L8H5FM.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2770851-80-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

VHA6L8H5FM

CAS Registry Number

2770851-80-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BECOTATUG VEDOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C180585

National Cancer Institute reference terminology for clinical and research data.

INN ID

13230

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Becotatug Vedotin

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Becotatug Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Becotatug Vedotin

Common Names & Synonyms

Anti-EGFR ADC MRG003

Anti-EGFR Antibody-drug Conjugate MRG003

H-gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV4-4*08 (79.4%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV6-21*02 (89.5%) -IGKJ2*03 (100%), CDRIMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (228-228'': 231-231'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHOS, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 222, 228, 231, 214', 222'', 228'', 231'' and 214''' with a group consisting of (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin)

Immunoglobulin G1-kappa, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE)

Recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E

antibody drug conjugate (ADC) composed of a recombinant humanized anti-human Epidermal growth factor receptor (EGFR) monoclonal antibody JMT101 conjugated with the cytotoxic small molecule MMAE

becotatug vedotin [INN]